Physician profile
Benjamin Scott Cunningham
NPI 1609214626
$3,470.77
in general payments reported to CMS, 2019-2025
20 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $322 · 2021: $262 · 2022: $855 · 2023: $362 · 2024: $637 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $1,155.09 | 2020-2025 | Xcopri |
| Livanova USA, INC. | $762.77 | 2020-2022 | |
| Ucb, INC. | $446.68 | 2019-2024 | Briviact, Rystiggo |
| Neurelis, INC. | $273.68 | 2023-2024 | Valtoco |
| Neuropace, INC. | $171.85 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $116.00 | 2022 | |
| Biogen, INC. | $97.74 | 2025 | Vumerity |
| Merz North America, INC. | $70.98 | 2020 | |
| Immedica Pharma US, INC. | $51.38 | 2023-2024 | |
| Greenwich Biosciences, INC. | $49.65 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $49.07 | 2025 | Acthar |
| Alnylam Pharmaceuticals INC. | $38.66 | 2024-2025 | Amvuttra |
| Abbvie INC. | $36.92 | 2023-2025 | Duopa |
| Eisai INC. | $30.64 | 2024 | |
| Amneal Pharmaceuticals LLC | $26.70 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $22.38 | 2020 | |
| Sunovion Pharmaceuticals INC. | $18.41 | 2022 | |
| Lundbeck LLC | $18.36 | 2019 | |
| Acadia Pharmaceuticals INC | $17.14 | 2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $16.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.